Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even BiggerIn the latest annual survey in Barron's of professional investors Johnson and Johnson (NYSE: JNJ) was rated the world's most respected company," reports Ron Rowland and Brandon Clay.
In Invest With an Edge, the advisors look at the 123-company, which he selects as " a solid healthcare pick in a strong long-term uptrend."
"This New Jersey-based company has come a long way since corner drugstores sold their baby powder. Beginning as a pioneer in sterile medical supplies, they expanded into pharmaceuticals and related consumer products.
"Over the years, they've released ubiquitous brands such as Band-Aid, Rogaine, Listerine, Tylenol, even Splenda. Johnson and Johnson has become a household name.
"However, Johnson & Johnson is a healthcare company with deeper product lines; it is ivided into three segments: Consumer, Pharmaceutical and Medical Devices & Diagnostics.
"Their strong brand presence undergirds their consumer products, especially in a weak market. In addition, investors expect their pipeline of new drugs to support future growth in that division.
"Finally, their reputation precedes them in nearly every venture they undertake, a vote of confidence for the future of the company.
"Perhaps the most important aspect of JNJ is how well it's performed in the last year. As other companies have been humbled by the market, JNJ has withstood the headwinds of a downturn.
"JNJ has risen +16%, an astounding bounce for such a large company in this market. Technically, JNJ just broke out of 3 ½ year congestion last month.
"Right now, it appears that break will hold. We expect JNJ to go even higher. For a solid healthcare pick in a strong uptrend, go with Johnson & Johnson."
Steven Halpern's TheStockAdvisors.com offers a daily look at the latest market commentary and favorite stock picks and investment ideas from the nation's leading financial newsletter advisors.
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
